Global Alimta Market Size, Share & Trends Report, by Product (100mg and 500mg), by Application (Pleural Mesothelioma and Non-Small Cell Lung Cancer) Forecast (2022-2028)

The global alimta market is anticipated to grow at a significant CAGR during the forecast period (2022-2028). Alimta is a prescription medicine used to treat symptoms of pleural mesothelioma and non-small cell lung cancer. The rise in the prevalence of lung cancer is anticipated to drive the growth of the global alimta market during the forecast period. For instance, according to the data published by the American Cancer Society (ACS) in 2022, approximately 13.0% of all lung cancers are SCLC and, 84.0% are non-small cell lung cancer (NSCLC). Moreover, lung cancer is the leading cause of mortality in both men and women accounting for 25.0% of all cancer mortalities. Further, lung cancer is most prevalent in the geriatric population. As per the ACS in 2022, approximately 236,740 new lung cancer cases have been identified out of which 117,910 are in men and 118,830 are identified in women. Also, 130,180 mortalities occurred due to lung cancer.

According to the data published by National Center for Biotechnology Information (NCBI) in 2021, the prevalence of pleural mesothelioma is approximately 2500 cases annually in the US and lung cancer incidence is 16000 cases annually in the US. Further, the majority of pleural mesothelioma cases in the US are associated with a history of asbestos. Moreover, as per the same source, pleural mesothelioma occurs after the fifth decade of life with an average age of diagnosis of 72 and a history of asbestos exposure of 2 to 4 decades before a diagnosis of the disease. Thus, owing to the rise in the incidence of pleural mesothelioma across the globe, the global alimta market is anticipated to grow at a significant rate during the forecast period

Looking towards the demand for alimta , key market players are adopting various strategies including mergers & acquisitions, geographical expansion, partnerships and collaborations, and new product launches, to stay competitive in the market. For instance, in January 2022, Eagle Pharmaceutical has announced the commercial availability of its product “Pemfexy”. Pemfexy is ready to use liquid to treat nonsquamous non-small cell lung cancer and mesothelioma. Moreover, in February 2020, Eagle Pharmaceutical had received the USFDA approval for Pemfexy, following the settlement agreement of patent litigation with Eli Lilly &Co in December 2019. Further, in December 2021, Eli Lilly &co has announced that PD-1 inhibitor Sintilimab has been included in the updated in the National Reimbursement Drug List (NRDL) for all approved indications, according to the latest announcement from the China National Healthcare Security Administration (NHSA).

In June 2021, Zydus Cadila had received tentative approval from USFDA to market pemetrexed for injection in the strength of 100mg, 500mg, and 1000mg, single-dose vials. These injections are used to treat certain types of cancers such as lung cancer and mesothelioma. Moreover, in January 2019, Eli Lilly &Co had received USFDA approval for the new indication of Alimta in combination with Keytruda, developed and marketed by Merck &Co. Alimta in combination with Keytruda is used for the first-line treatment of patients with metastatic non-small lung cancer with no ALK genomic tumor aberrations. Thus, such product launches coupled with strategic collaborations are anticipated to accelerate the growth of the global alimta market during the forecast period.

 

Market Coverage

• The market number available for – 2021-2028
• Base year- 2021
• Forecast period- 2022-2028
• Segment Covered-
  • By Product
  • By Application
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
• Competitive Landscape- Abbot Healthcare, Eli Lilly & Co., Cadila Healthcare Ltd, and Eagle Pharmaceuticals, Inc. among others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How has COVID-19 impacted the market?
  • Deviation from the pre-COVID-19 forecast
  • Most affected region and segment
• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Alimta Market Report by Segment

By Product

• 100 mg
• 500 mg

By Application

• Non-small Cell Lung Cancer (NSCLC)
• Pleural Mesothelioma

Global Alimta Market Report by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa